Apolipoprotein (APO) C1 is a 6.6-kDa
protein present in plasma and associated with
lipoproteins. Using hyperinsulinemic-euglycemic clamp tests, we previously found that in APOC1 transgenic mice, the whole-body
insulin-mediated
glucose uptake is increased concomitant with a decreased
fatty acid uptake. These latter results are confirmed in the present study, showing that APOC1 transgenic mice exhibit a 50% reduction in the uptake of the
fatty acid analog 15-(p-iodophenyl)-3-(R,S)-methyl
pentadecanoic acid in white adipose tissue stores. We next investigated whether APOC1 overexpression can modulate the initiation and/or development of
obesity and
insulin resistance. When crossbred on the genetically obese ob/ob background, APOC1 transgenic mice were fully protected from the development of
obesity compared with ob/ob only mice, as reflected by a strong reduction in
body weight (21 +/- 4 vs. 44 +/- 7 g), total adipose tissue stores (15 +/- 3 vs. 25 +/- 3% body wt), and average adipocyte size (7,689 +/- 624 vs. 15,295 +/- 1,289 microm(2)). Although less pronounced, APOC1 overexpression also reduced
body weight on a wild-type background, solely due to a reduction in adipose tissue. Furthermore, despite elevated plasma
free fatty acid and
triglyceride levels, APOC1 overexpression significantly improved
insulin sensitivity in ob/ob mice, as demonstrated by a strong reduction in plasma
glucose and
insulin levels, as well as a better performance in the
glucose tolerance test. In conclusion, a marked reduction in the uptake of
fatty acids into adipocytes may underlie the protection from
obesity and
insulin resistance in transgenic mice overexpressing
human APOC1.